Acellular Human Amniotic Membrane Scaffold with 15d-PGJ2 Nanoparticles in Postinfarct Rat Model
Julio Cesar Francisco1,2, Laercio Uemura3, Rossana Baggio Simeoni3,4
1Laboratory of Cardiovascular Surgery and Pathophysiology of Circulation, Department of Cardiopneumology, Heart Institute (Incor), Sao Paulo University Medical School, São Paulo, Brazil.
Tissue Engineering. Part A
|June 4, 2020
Summary
Human Decellularized Amniotic Membrane Scaffold (AHAS) combined with 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) improved heart function in rats post-myocardial infarction. This combination therapy reduced fibrosis and promoted cardiomyocyte regeneration, enhancing ejection fraction and preventing ventricular dilation.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Biomaterials Science
Background:
- Myocardial infarction leads to cardiomyocyte loss and heart failure due to limited regenerative capacity.
- Amniotic membrane offers growth factors, while 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) exhibits anti-inflammatory effects, suggesting potential synergistic benefits for cardiac repair.
Purpose of the Study:
- To evaluate the efficacy of a Human Decellularized Amniotic Membrane Scaffold (AHAS) loaded with 15d-PGJ2 in improving ventricular function in a rat model of postinfarct ventricular dysfunction.
- To compare the therapeutic effects of AHAS alone versus AHAS combined with 15d-PGJ2 on cardiac remodeling and regeneration.
Main Methods:
- Myocardial infarction was induced in rats, followed by echocardiographic assessment of ventricular function (LVEF, LVEDV, LVESV) in control, AHAS, and AHAS + 15d-PGJ2 groups.
- Histological analysis included Gomori trichome, Sirius Red staining, and immunohistochemistry for CD31 and connexin 43 (Cx43) to evaluate infarct size, fibrosis, vascularization, and cardiomyocyte proliferation.
Main Results:
- The AHAS + 15d-PGJ2 group showed a significant increase in ejection fraction and a decrease in ventricular volumes (LVEDV, LVESV) compared to the control group, indicating anti-remodeling effects.
- Histopathology revealed reduced infarct size and collagen type 1 deposition in both AHAS and AHAS + 15d-PGJ2 groups.
- Increased CD31 and Cx43 expression in the infarcted area of AHAS and AHAS + 15d-PGJ2 treated rats suggested neovascularization and cardiomyocyte proliferation.
Conclusions:
- AHAS loaded with 15d-PGJ2 effectively improves ventricular function and promotes cardiac regeneration in a postinfarction rat model.
- The combination therapy demonstrates significant anti-fibrotic and anti-remodeling effects, enhancing myocardial repair through increased vascularization and cardiomyocyte proliferation.
- This study highlights the therapeutic potential of combining biomaterial scaffolds with specific bioactive molecules for treating heart failure post-myocardial infarction.
